Evidence map›Paper›PMID 25136079›Full record

GuidelineThe British journal of ophthalmology2014

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello and 1 more

2 registry-linked trialsOpen access · hybridAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in The British journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 328 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
328citing papers in PubMed, 10 pooled it
29.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01318941 completednot on this map

LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes

TypeobservationalSponsorNovartis PharmaceuticalsRan2011 to 2016Enrolled30,490ConditionsWet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein OcclusionArmsRanibizumab
NCT05710471 phase4completednot on this mapstarted 2022, after this paper: background citation

Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective Study

TypeinterventionalSponsorThe University of Hong KongRan2022 to 2023Enrolled30ConditionsAge-Related Macular DegenerationArmsBrolucizumab, Aflibercept
3 · Its place in the literature

Who cites it

328 citing papers in PubMed, 10 syntheses or guidelines pooled it, 633 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

268 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 10 countries.

Ursula Schmidt-ErfurthDepartment of Ophthalmology, Medical University, Vienna, Austria.
Victor ChongOxford Eye Hospital, Oxford University Hospitals, Oxford, UK.
Anat LoewensteinDepartment of Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel.
Michael LarsenDepartment of Ophthalmology, Glostrup Hospital and University of Copenhagen, Copenhagen, Denmark.
Eric SouiedHôpital Intercommunal de Créteil, Paris, France.
Reinier SchlingemannMedical Retina Unit and Ocular Angiogenesis Group, Department Of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands.
Bora EldemDepartment of Ophthalmology, Hacettepe University, School of Medicine, Ankara, Turkey.
Jordi MonésCentro Médico TEKNON, Director Institut de la Màcula i de la Retina, Barcelona, Spain.
Gisbert RichardDepartment of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Francesco BandelloDepartment of Ophthalmology, University Vita-Salute; Scientific Institute San Raffaele, Milano, Italy.
European Society of Retina Specialists
Academic Medical Center · NLBarcelona Macula Foundation · ESGlostrup Hospital · DKHacettepe University · TRHôpital Intercommunal de Créteil · FRMedical University of Vienna · ATOxford University Hospitals NHS Trust · GBUniversität Hamburg · DEVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledAge-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients. TRIAL REGISTRATION NUMBER: NCT01318941.

Indexed as

Angiogenesis InhibitorsChoroidal NeovascularizationEvidence-Based MedicineHumansLight CoagulationTomography, Optical CoherenceVascular Endothelial Growth Factor AWet Macular DegenerationAngiogenesis InhibitorsVascular Endothelial Growth Factor AVEGFA protein, humanRetina

Identifiers

PMID25136079
PMCPMC4145443
OpenAlexW2125587232

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.